MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 06-29-2023
Idera Pharmaceuticals ROCE Ratio 2011-2026 | IDRA
Annual ROCE Ratio Idera Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -235.23 | -93.96 | -103.72 | 652.9 | -88.43 | -61.37 | -37.31 | -57.16 | -87.32 | -55.98 | -297.38 | -132.52 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 652.9 | -297.38 | -49.79 |
Quarterly ROCE Ratio Idera Pharmaceuticals
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -115.21 | -86.48 | -104.56 | -77.73 | -72.37 | -61.81 | -53.6 | -27.32 | 1.5 | 31.42 | 133.38 | 227.13 | 321.46 | 306.94 | 288.38 | 167.85 | 39.26 | -75.73 | -89.34 | -84.4 | -78.98 | -47.77 | -60.33 | -59.26 | -52.38 | -38.22 | -51.94 | -53.1 | -55.22 | -43.98 | -65.92 | -74.14 | -78.05 | -61.8 | -76.23 | -68.72 | -60.52 | -37.28 | -710.36 | -1369.02 | -2112.14 | -2205.24 | -2250.4 | -1622.47 | -919.63 | -153.23 | -45.16 | -51.26 | -56.81 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 321.46 | -2250.4 | -242.67 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 3.97 | 6.43 % | $ 9.55 B |  Australia |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M |  USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M | France |
 |
Akari Therapeutics, Plc
AKTX
|
-60.98 | $ 5.12 | 11.55 % | $ 345 B |  Britain |
 |
Aligos Therapeutics
ALGS
|
-164.32 | $ 7.66 | 3.23 % | $ 75.7 M | USA |
 |
Allakos
ALLK
|
-116.14 | - | - | $ 28.6 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
63.56 | $ 320.13 | -3.98 % | $ 41.9 B | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
17.8 | $ 21.81 | 0.6 % | $ 1.02 B | USA |
 |
Burford Capital Limited
BUR
|
14.24 | $ 4.67 | -1.37 % | $ 766 M | Britain |
 |
Applied Therapeutics
APLT
|
394.73 | - | - | $ 8.42 M | USA |
 |
BioNTech SE
BNTX
|
-4.81 | $ 102.12 | 2.66 % | $ 27.2 B | Germany |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-664.7 | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 3.08 | -4.94 % | $ 5.07 M |  Israel |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
72.06 | $ 1.35 | -12.9 % | $ 347 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
211.07 | $ 4.26 | 0.47 % | $ 456 M | USA |
 |
AstraZeneca PLC
AZN
|
11.12 | - | - | $ 96.9 B | Britain |
 |
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 24.19 | -1.59 % | $ 3.08 B | USA |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
163.63 | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-151.88 | $ 1.61 | 8.05 % | $ 428 M | Britain |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
AVROBIO
AVRO
|
10.76 | - | 1083.1 % | $ 745 M | USA |
 |
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
-125.56 | - | - | $ 546 M | USA |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Cidara Therapeutics
CDTX
|
-107.83 | - | - | $ 1.41 B | USA |
 |
BioXcel Therapeutics
BTAI
|
52.86 | $ 1.07 | 1.9 % | $ 13.1 M | USA |
 |
Cabaletta Bio
CABA
|
-153.72 | $ 3.52 | 3.53 % | $ 354 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-34.79 | - | - | $ 3.45 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-252.54 | - | 3.16 % | $ 1.9 M | USA |
 |
ChromaDex Corporation
CDXC
|
21.27 | - | -0.88 % | $ 598 M | USA |